Biopeople: - Dansk Biotek
Transcription
Biopeople: - Dansk Biotek
Innovation across disciplines Biopeople: Danish Innovation Cluster for Life & Health Sciences GÅ-Hjemmøde Horizon2020 23. januar 2014 Niels Westergaard, PhD, Dr pharm Science and Innovation Network Manager www.biopeople.dk Biopeople Innovation across disciplines • We focus on setting up: • cross disciplinary projects • public private partnerships • internationalisation. • To reach these strategic goals, we use the following services: • matchmaking events • knowledge transfer, • innovation projects • strategy development. Cartoons: Jens Hage; www.hage.dk 3 Innovation across disciplines Biopeople receives the European Cluster Excellence Initiative (ECEI) Gold Label of Cluster Management Excellence in June 2013. Based on expert assessment of 31 quality indicators Endorsed by the European Commission Biopeople is the first European Life Science Network to obtain that recognition 4 Horizon 2020 Innovation across disciplines New framework programme for Research and Innovation (2014-2020) Biopeople to take an active role to stimulate the formation of strong consortiums within life sciences and be an active player in reference groups and advisory boards Reference group: • Health, Demographic Change and Wellbeing • Food Security and Biobased Economy Matchmaking Cartoons: Jens Hage; www.hage.dk Horizon 2020 http://www.biopeople.dk/index.php?id=732 Innovation across disciplines Innovation across disciplines European Patients Academy on Therapeutic Innovation (EUPATI) http://www.patientsacademy.eu – [email protected] The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115334, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies. Innovation across disciplines IN2LifeSciences: Access to Market, Technology and Financing fore SMEs Shared among 8 bioregions, of which Denmark is one ~ 250 incentives: €500, €4000 or €7000 Regional Access Brokers Easy access to facilities and experts (this is not a logo) Biopeople den 23. januar 2014 Anne-Mette Mikkelsen EuroCenter [email protected] Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation EuroCenter – National Contact Point (NCP) Vejledning til danske FP-7 og Horizon 2020 deltagere Vejledning og rådgivning – fra projektidé til projektafslutning (via telefon, email, individuelle møder) Vejledning ift. juridiske og økonomiske regler Tæt kontakt til Europa Kommissionen Ansøgningsvejledning Kurser om ansøgningsskrivning, rapportering, koordinatorrollen mm. www.rammeprogram.dk Kontakt: Telefon: 35446240 E-mail: [email protected] Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Hvorfor 70 mia. € til forskning og innovation ? • Styrke Europas position indenfor videnskab på den globale scene • Fremme Europas industrielle lederskab • Adressere store samfundsmæssige udfordringer skabe vækst og beskæftigelse i Europa Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Budget: 77 milliarder euros INDUSTRIAL LEADERSHIP EXCELLENT SCIENCE European Research Council 17% Leadership in enabling and industrial technologies 17,6% Future and Emerging Technologies Access to risk finance 3,69% 3,5% Marie Sklodowska-Curie actions 8% Innovation in SMEs SOCIETAL CHALLENGES Health, demographic change and well-being; Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy 5% Secure, clean and efficient energy; 7,7% 0,8% Research Infrastructures 9,7%7 % Smart, green and integrated transport; 8,23% 3,23% Widening Participation: 1,06% Science with and for society: 0,6% EIT: 3,52% JRC: 2,47% Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Climate action, resource efficiency and raw materials; 4% Inclusive, innovative and reflective societies. 1,7% Secure Societies 2,2% Én type tilskudsrate per projekt Projekttyper Tilskudsrate Research and Innovation Actions 100 % + 25 % Innovation Actions 70 % + 25 % (100 % til non-profit) Coordination & Support Actions 100 % + 25 % Dvs. at alle støtteberettigede udgifter i f.eks. et forskningsprojekt støttes med 100 % + 25 % overhead uanset aktivitets- og partnertype, 70 % + 25 % i et innovationsprojekt (demonstration/close to market a.)… Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Muligheder for SMVer (I) Forsknings- og innovationsprojekter, som udbydes i arbejdsprogrammer (WP) under Leadership in enabling and industrial technologies (søjle 2) og Societal Challenges (søjle 3). Time to grant: 8 måneder (5+3) Konsortiekrav: Min. 3 partnere fra 3 forskellige EU-lande ell. ass. lande Varighed: Typisk 3-5 år Budgetstørrelse: Typisk 3-9mio euros Spg vedr. wp for bioteknologi og bioøkonomi Kontakt NCP Ulrik K. Olsen Telefon: 72318281 E-mail: [email protected] Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Spg vedr. wp for sundhed Kontakt NCP Kim Kryger Telefon: 72318288 E-mail: [email protected] Muligheder for SMVer (II) Fast track to innovation (projekttype fra 2015), som udbydes i arbejdsprogrammer (WP) under søjle 2 og 3 Bottom up – indenfor rammerne af det givne arbejdsprogram Forventet tilskud ca. 3 millioner euros Time-to grant max 6 måneder Løbende ansøgningsfrist Små konsortier (3-5 partnere) Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Muligheder for SMVer (III) Marie Sklodowska Curie Actions (program under søjle 1) “gratis” forsker eller ph.d (udstationering til virksomheden) ITN- call’et (støtte til uddannelse af ph.d.-er) - smv’en bliver del af en “ph.d-skole” med vidensinstitutioner - smv’en bliver tilknyttet netværket og tager imod en ph.d.-studerende i en periode RISE-callet (støtte til staff exchange) - smv’en deltager i et forskningsprojekt med vidensinstitutioner og får tilskud fra EU til udveksling af personale Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Spg vedr. wp for MSC Kontakt NCP Bodil Palmberg Telefon: 72318263 E-mail: [email protected] Muligheder for SMVer ud (IV) Eurostars (NB - særligt program med national medfinansiering). Primær målgruppe: innovations- og forskningsaktive SMV’er (anvender mindst 10 % af deres omsætning eller af deres fuldtidsansatte på FoU aktiviteter). Medfinansiering af forsknings- udviklings- og demonstrationsaktiviteter. Tværnationale konsortier (min. 2 deltagere fra 2 lande). Varighed: maximalt 3 år og 2 år til markedsføring efter projektafslutningen. Biotek-projekter skal mindst være klar til klinisk fase ét to år efter projektafslutningen. Uafhængigt internationalt bedømmelsespanel. Svar på ansøgning inden for 4-5 måneder. SMV’er kan få op til 50 % af projektomkostningerne dækket. Det maksimale tilskudsbeløb pr. projekt er 300.000 € til de danske deltagere. De danske tilskud dækker primært lønudgifter. Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Spg. vedr. EuroStars Kontakt: Lisbet Elming Telefon: 72318252 E-mail: [email protected] Muligheder for SMVer (V) Budget: ca. 3 mia euros SMV-instrument (projekttype, som udbydes i arbejdsprogrammer (WP) under søjle 2 og 3) Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Fase 1 Konsortiekrav: Min. 1 smv Concept & Feasibility Assessment Ansøgningsfrist: Løbende ansøgning Time to grant: 3 måneder Projektvarighed: 6 måneder Budgetstørrelse: 50.000 euros (70 %) Ansøgning: 10 sider Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Fase 2 Demonstration Market Replication Research Development Miniaturisation Testing Piloting Prototyping Scaling up Kan søges direkte uden forudgående deltagelse i fase 1 Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Konsortiekrav: Min. 1 smv Ansøgningsfrist: Løbende ansøgning Time to grant: 6 måneder Projektvarighed: 12-24 måneder Budgetstørrelse: Typisk 0.5-2.5 mio euros (70 %) Ansøgning: 30 sider Concept & Feasibility Assessment Demonstration Market Replication Research Development Miniaturisation Testing Piloting Prototyping Scaling up Support – No direct funding IDEA business coaching throughout the project Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation MARKET Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Nyttige links Deltagerportalen (participant portal) hvor al information om H2020 findes: http://ec.europa.eu/research/participants/portal/desktop/en/home.html Genvej til arbejdsprogrammer, regler for deltagelse, ansøgningsskabeloner mm: http://ec.europa.eu/research/participants/portal/desktop/en/funding/reference _docs.html Ansøgningsskabelon fase 1 SMV-instrumentet: http://ec.europa.eu/research/participants/data/ref/h2020/call_ptef/pt/h2020call-pt-sme-1_en.pdf Ansøgningsskabelon fase 2 SMV-instrumentet: http://ec.europa.eu/research/participants/data/ref/h2020/call_ptef/pt/h2020call-pt-sme-2_en.pdf Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation EUopSTART EUopSTART yder tilskud til danske virksomheders og videninstitutioners forberedende arbejde med at deltage i udvalgte europæiske og internationale forskningsprogrammer. EUopSTART giver støtte til forberedelse af ansøgninger til Horizon 2020 Puljen åbner igen 1. juli 2014 Kontakt Helle Poulsen Telefon: 72318251 E-mail: [email protected] www.fivu.dk/euopstart Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation Ea Elisabeth Bauchy Telefon: 72318247 E-mail: [email protected] Ministeriet for Forskning, Innovation og Videregående Uddannelser Styrelsen for Forskning og Innovation www.eusupport.dk January, 2014 Copenhagen Bio Science Park Experience gained from working in EU framework programs Peter Mouritzen, MSc, PhD VP R&D Agenda 2 ● Introduction to Exiqon today ● How did we get there ● A historic perspective on the role of EU FP projects ● Exiqon Roles in EU FP projects ● Workload of roles ● Internal guidelines Exiqon at a glance Highlights Locations • Based on proprietary LNA™ detection technology • Established one-stop shop for miRNA products • Promising diagnostic pipeline based on miRNA • 214 patents and patent applications (114 issued) cover products, pipeline and miRNA biomarkers Exiqon facilities Distributors Business divisions Life Sciences • Exiqon Life Sciences combines leading-edge scientific expertise in gene expression with our proprietary LNA™ technology. Our products, services and scientific staff enable life science researchers to make groundbreaking discoveries Diagnostics Exiqon Diagnostics is the leader in providing technologies for miRNA biomarker detection. Exiqon Diagnostics is dedicated in collaboration with partners to develop novel molecular diagnostic tests for early detection of diseases and knowledge based treatment selection. Exiqon at a glance - We took innovation conducted at universities into commercial success 4 • Exiqon develops, manufactures and sell products for genetic testing addressing a 12 billion USD market • 98% of products sold are exported. 60% are exported out of EU mDKK • >75 highly educated employees (40% has a Ph.D.) from >10 nationalities • Knowhow: Molecular & cell biology, (bio)chemistry, bioinformatics, robotics and IT 25 • Raised 600 mDKK in risk capital 20 15 Our proprietary technology Exiqon in-licensed was invented the technology at U of CPH and Osaka University First product launched 10 5 0 1997 2000 2004 Q1 2006 Q4 2012 LNA™ technology overview LNA™ technology increases binding affinity • LNA is a bicyclic high affinity RNA mimic with the sugar ring locked in the 3’-endo conformation • • • • Stable A-helix with good base-stacking • • Obeys Watson-Crick base-pairing rules Increased Tm (Tm increases by 2 - 8ºC per base) Improved mismatch discrimination High sensitivity and specificity in hybridization assays Easy to implement in standard oligo synthesis K. Bondensgaard et al., Chem. Eur. J. 2000, 6, 2687 M. Petersen et al., J. Am. Chem. Soc. 2002, 124, 5974 MicroRNA research: Broad product portfolio Exiqon Diagnostic Pipeline Diagnostic Product Development Colorectal Cancer (Recurrence stage II test ) Colorectal Cancer (Early detection diagnostic test) Prostate Cancer (Diagnostic and prognostic test) NGS precision medicine RUO kit in 2014 Synergies within business areas Life Sciences • • • Diagnostics Molecular tools microRNA profiling platforms Protocols • • • microRNA as biomarkers Biofluids – serum, plasma, urine, CSF Protocols • • • • Exiqon Core lab Centralized expertise In house experts with our own products Protocol validation Experience & Innovation Exiqon Services Important events in building one-stop shop for miRNA products Wienholds et al Science 4000 3500 Papers 3000 2500 2000 Development Development Start RIBOREG & of 1st miRNA of of first miRNA Development LNA™ PCR miRNA LNA™ LNA™ ISH probesmicroarray 1500 1000 500 0 lin-4, critical for C.elegans developmental timing Development of 2nd miRNA LNA™ PCR miRNAs found in mouse & human miRNAs implicated in cancer miRNAs implicated in viral infection miRNA papers per year according to PubMed Excellent timing for product development and perfect application for LNA™ Exiqon in 2004 • ~20 employees • Large R&D organization • LNA™ oligo business 10 RIBOREG FP6 project • 36 month project duration • 250 T EUR Grant • 9 partners • Work package leader role RIBOREG Identification of putative precursors of si/mi RNAs WP1 Identifica tion of new large noncoding RNAs Transfer to WP3 or new non-coding RNAs for exp ression study WP5 Co-ordination and Management WP2 Identifica tion of new si/miRNA s, their precursors and targets Transfer to WP3 or new non-coding mi/si RNAs for expression studies WP3 Determin ation of the expressio n patterns of non-codin g RNA genes WP4 Dissectio n of molecula r mechanisms involving non-codin g RNAs Selection of most interesting non-coding RNAs for WP4 European Commission and the European Scientific and Industrial Communities Experiences from >7 EU FP projects 11 5-10 invites per year to join EU projects ● Roles ● Work Package leader ● Contributing partner ● Initiative taker ● Tasks ● ● ● ● Proposal writing coordination of reporting - Some workload own scientific reporting - Moderate workload Financial reporting Innovation at Exiqon - Publicly funded projects is one pillar in our innovation strategy Innovation at Exiqon: • Internal “Innovation Challenge” • In collaboration with customers • Based on public funding with academic partners We use externally funded programs to: • Access specific knowhow • Access to “key opinion leaders” • Get the products validated and tested • Get access to relevant biological material 12 EU funded programs have been instrumental to Exiqon 13 - Public funded projects work Program Number of partners Total budget/Exiqon budget Commercial outcome (Exiqon) Riboreg/FP6 9 Initiated 80% of our product portfolio Sirocco/FP6 20 16,0 / 0,6 mEUR Very limited Oncomirs/FP7 6 4,3 / 0,6 mEUR Development of the fastest growing product line Prosper/FP7 7 4,0 / 0,6 mEUR Launch March 2013 Colon cancer/HTF 4 42 / 28 mDKK Best selling product Riboreg was the most successful EU program so far – it was used by EU to showcase FP6: From concluding report: ” They note that the collaboration in the RIBOREG project has allowed speeding up the development of the LNA probe technology and Exiqon has been able to commercialize a number of products based on this technology” Learning from public funded programs 14 Learning: • The fewer partners the better • Project leadership is essential: Best when project leader is in company • Commercial outcome: The innovation is often applied in products for other markets than originally intended • Innovation from publicly funded programs only results in commercial success when it simultaneously is supported by risk capital e.g. Riboreg was launched in the financial “heydays” Without money, innovation is worth nothing - Access to risk capital is essential. 15 • Even within established organizations it is expensive to take new products to the global market • The actual product development, manufacturing processes, marketing and selling process cost more in working capital than received in public funding Demand for risk capital In SME’s (cash flow negative) that is funded by risk capital Innovation creates value once the need for risk capital is addressed 16 - We can do it much better E.g. on financial audit manuals On public funded innovation programs: FP7: 107pages + 96 pages HTF: 15 pages + 15 pages In FP7 programs, Exiqon has spend • Simplify management of public funded EU programs 5% of the budget on internal financial control • Increase focus on project management • Fund fewer programs with fewer participants but make programs more ambitious = better funded On commercialization of innovation: • It is very costly to take public funded innovation into commercial products • It takes time: In Life Sciences 5-10 years is common • We can only harvest the commercial potential if DK (EU) improve the access to risk capital Exiqon guidelines in considering participation 17 ● Hire a professional coordinator ● ● A lot of ressouces writing Interacting with the commision ● Don’t get involved if you have to do a lot of stuff you did not intend to ● Only participate if this will take you the way you planned anyway ● Ultimately, initiate the project yourself ● Challenges beeing a partner supermarket for consumables Summary ● EU projects may be a good way to ● Access specific knowhow ● Access KOLs ● Get the products validated and tested ● Get access to relevant biological material ● Consider alignment of project with overall company strategy ● Devote a partner role to project coordination Thank you Contact information: VP R&D Peter Mouritzen [email protected] Horizon2020 Netværksmøde Hos BioPeople 23. januar 2014. Christina Yoon Petersen EUhelp.dk – [email protected] - Tlf.: 29 25 45 66 Erfaring • Revideret for EU via Moore Stephens • Revideret FP6 via PwC • Afrapporteret Form C FP6 og FP7 via GEUS, KU og virksomheder. Horizon2020 Få hjælp fra en række aktører. • Private • Innovationsnetværk/BioPeople • Offentlige Styrelser • Universiteter/forskningsinstitutioner • GTS • Virksomheder • Udlandet Offentlige • EuroCenter • Agropark (partnerskab) • EU DK support • Innovationsnetværk/BioPeople • Universiteter: KU, DTU, Århus Universitet • GTS (halv offentligt) • Andre forskningsinstitutioner Private • Innovayt • 1stmile • Wiborg • Anders Bjerrum • Udenlandske (hyperion, G & H Associates Limited) • EUhelp • Revision: Deloitte eller PwC Regler og dokumentation Ansøgning: • Højteknologifonden (Innovationsfonden) - erfaring • Private/offentlige aktører Dokumentation/revisor: • EUhelp • Deloitte/PwC • Bogholder med erfaring fra fx en forskningsinstitution. • Eurocenter (inkl. Kurser) Netværk • BioPeople og Netmatch (Innovationsnetværk) • Kurser og arrangementer hos Eurocenter • Dansk Industri og Dansk Erhverv • Arrangementer hos universiteterne (Erhvervssamarbejder, forskerparker etc.) • Udenlandske universiteter/virksomheder. • EUhelps netværksarrangementer Netværksarrangement 23. maj 2014. • ”Adgang til finansiering” • I samarbejde med Deloitte. • Oplægsholdere. • Idéen med at hjælpe hinanden. • Fredagsbar. • Tidligere arrangementer